港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

药捷安康-B

53.150

-0.600-1.12%

成交量：26.56万

成交额：1,368.29万

市值：210.95亿

市盈率：-67.77

高：54.050

开：52.750

低：48.660

收：53.750

52周最高：58.050

52周最低：20.200

股本：3.97亿

香港流通股本：3.02亿

量比：1.46

换手率：0.09%

股息：- -

股息率：- -

每股收益(LYR):-0.784

净资产收益率：-41.98%

总资产收益率：-24.05%

市净率：36.86

市盈率(LYR):-67.77

市销率: - -

数据加载中...

总览公司新闻公告

药捷安康-B07月09日主力净流入11.9万元散户资金抛售

“IPO盛宴”强势回归

艾美达医药咨询

药捷安康-B07月08日主力净流出87.4万元散户资金买入

2025年港股IPO半年报——专题一：千亿募资破局 A to H 新消费创新药点燃市场

药捷安康-B涨超16%再创上市新高替恩戈替尼获FDA快速通道认证

61岁医药大佬吴永谦，收获一个IPO！市值突破110亿

Ofweek维科网

药捷安康－Ｂ(02617)股价大幅上升16.695%，现价港币$33.9

阿斯达克财经

四成半IPO募资超1亿美元，上半年44家香港上市、募资1071亿 | 香港IPO市场2025年

瑞恩资本Ryanbe...

药捷安康-B07月02日遭主力抛售79.4万元

上半年港股IPO吸金超千亿科技新秀引爆打新潮

21世纪经济报道

智通特供 | 恒指半年检：“港股通冲退榜”显示，这22只股票或将纳入港股通

港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快公司在细分行业研发领先

61岁医药大佬吴永谦，收获一个IPO！市值突破110亿

5家创新药企完成新一轮融资，包括药捷安康、华卫恒源等

18A新贵，暴涨78%

药捷安康-B06月27日获主力加仓87.4万元

药捷安康-B上市一周累涨逾100%！核心产品替恩戈替尼获FDA快速通道认证

老虎资讯综合

药捷安康-B续涨7%，总市值逼近100亿港元；该股昨日上市首日飙涨近79%

老虎资讯综合

【湾区早参】深圳二手房在售量超过72000套；广州发布智能网联汽车发展计划

药捷安康-B(02617.HK)：替恩戈替尼(TT-00420)被授予治疗MCRPC快速通道认证

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02617/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":53.15,"timestamp":1756194178093,"preClose":53.75,"halted":0,"volume":265580,"delay":0,"floatShares":301666673,"shares":396897633,"eps":-0.7842815634688939,"marketStatus":"交易中","change":-0.6,"latestTime":"08-26 15:44:05","open":52.75,"high":54.05,"low":48.66,"amount":13682917,"amplitude":0.100279,"askPrice":53.3,"askSize":2500,"bidPrice":53.05,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.7842815634688939,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1756195800000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":53.75,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":1.455069,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":301666673,"roa":"-24.05%","roe":"-41.98%","lyrEps":-0.784282,"volumeRatio":1.455069,"shares":396897633,"dividePrice":0,"high":54.05,"amplitude":0.100279,"preClose":53.75,"low":48.66,"week52Low":20.2,"pbRate":"36.86","week52High":58.05,"institutionHeld":0,"latestPrice":53.15,"committee":-0.666667,"eps":-0.7842815634688939,"divideRate":0,"volume":265580,"delay":0,"ttmEps":-0.7842815634688939,"open":52.75,"prevYearClose":13.15,"prevWeekClose":54.75,"prevMonthClose":37.95,"prevQuarterClose":30.15,"fiveDayClose":51.7,"twentyDayClose":40.9,"sixtyDayClose":13.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2025-08-25","current":-71.114754,"percent":0.066667,"low":-72.789898,"twenty":-63.292817,"median":-44.380409,"eighty":-39.630155,"high":-17.403134,"avg":-49.174295,"sd":13.084245,"marketCap":21333247773},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-25","current":-71.114754,"twenty":-63.292817,"median":-44.380409,"eighty":-39.630155,"marketCap":21333247773}],"updateTime":1756186957066},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550680177","title":"药捷安康-B07月09日主力净流入11.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550680177","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550680177?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 16:15","pubTimestamp":1752048956,"startTime":"0","endTime":"0","summary":"07月09日, 药捷安康-B股价涨1.15%，报收30.85元，成交金额1391.2万元，换手率0.15%，振幅10.16%，量比0.73。药捷安康-B今日主力资金净流入11.9万元，上一交易日主力净流出87.4万元。该股近5个交易日上涨11.17%，主力资金累计净流出108.2万元；近20日主力资金累计净流入641.3万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170532a43ff84b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170532a43ff84b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2550683564","title":"“IPO盛宴”强势回归","url":"https://stock-news.laohu8.com/highlight/detail?id=2550683564","media":"艾美达医药咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550683564?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 15:00","pubTimestamp":1752044427,"startTime":"0","endTime":"0","summary":"2025年7月1日，上交所官网显示，武汉禾元生物科技股份有限公司科创板IPO成功通过上交所上市审核委员会审议，成为科创板第五套上市标准重启后首家过会的IPO企业。2025年的A股生物医药IPO市场呈现出积极且结构化的新格局。亦诺微医药、微脉、百力司康等数十家医健企业已向港交所递交上市申请，排队等候上市，场面火爆，预示着下半年IPO热潮将持续。此外，多个IPO项目获得投资者热烈追捧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709150735a69ec54e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709150735a69ec54e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU1064131003.USD","LU1997245177.USD","BK0012","600276","159982","BK0239","LU1655091616.SGD","BK0196","BK0028","02561","01877","LU1064130708.USD","LU0405327148.USD","LU2488822045.USD","02617","LU1997244956.HKD","LU2148510915.USD","BK0183","LU1969619763.USD","LU0405327494.USD","LU2495084118.USD","LU1997245094.SGD","BK0060","02592","LU2328871848.SGD","LU1328615791.USD","BK0188"],"gpt_icon":0},{"id":"2549121985","title":"药捷安康-B07月08日主力净流出87.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2549121985","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549121985?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 16:15","pubTimestamp":1751962536,"startTime":"0","endTime":"0","summary":"07月08日, 药捷安康-B股价跌6.15%，报收30.50元，成交金额1118.0万元，换手率0.12%，振幅6.46%，量比0.45。药捷安康-B今日主力资金净流出87.4万元，上一交易日主力净流出0万元。该股近5个交易日上涨1.16%，主力资金累计净流出199.5万元；近20日主力资金累计净流入629.5万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165413a69cc758&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165413a69cc758&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2548151360","title":"2025年港股IPO半年报——专题一：千亿募资破局 A to H 新消费 创新药点燃市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2548151360","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548151360?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 18:26","pubTimestamp":1751624760,"startTime":"0","endTime":"0","summary":"2025年上半年，共7家A股公司完成港股IPO，合计募资超770亿港元，占IPO总额的72%，直接推升港股IPO募资额复苏。展望2025年下半年，将有数家A股公司登陆港交所，预计募资规模也将比肩上半年A to H募资额水平，进一步巩固大盘股主导地位。工业材料等板块IPO颓势 募资认购收益全面遇冷在A to H、消费、医疗医药等新经济赛道的狂欢图景中，工业、材料、信息技术、金融板块尽显颓势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704182723a72eaafe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704182723a72eaafe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","HSCEI","HSTECH","02565","02619","600276","BK1161","BK1574","603288","02617"],"gpt_icon":1},{"id":"2548527413","title":"药捷安康-B涨超16%再创上市新高 替恩戈替尼获FDA快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2548527413","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548527413?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 14:49","pubTimestamp":1751611744,"startTime":"0","endTime":"0","summary":"药捷安康-B午后涨超16%，高见34港元，再创上市新高。截至发稿，涨16.18%，报33.75港元，成交额2089.53万港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼，已获美国食品药物管理局授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，替恩戈替尼目前处于全球三期注册实验的多靶点激酶抑制剂，靶向FGFR/VEGFR、JAK和Aurora激酶发挥抗肿瘤作用，目前正在美国与中国进行的临床试验显示，其在多种实体瘤治疗中具有疗效潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704145503a4cedc3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704145503a4cedc3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2548546503","title":"61岁医药大佬吴永谦，收获一个IPO！市值突破110亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2548546503","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548546503?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 14:07","pubTimestamp":1751609239,"startTime":"0","endTime":"0","summary":"6月23日，创新药企业药捷安康在港上市，上市首日，其股价大涨超78%。此后数个交易日，药捷安康股价持续上涨，目前其市值已突破100亿港元。截至最新收盘，药捷安康总市值为110亿港元。若以此计算，吴永谦身价已经超过了36亿港元。2024年6月，药捷安康再次冲击港交所IPO，直至本次才上市成功。原文标题 : 61岁医药大佬吴永谦，收获一个IPO！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070414074197998653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070414074197998653&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02617","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2548515283","title":"药捷安康－Ｂ(02617)股价大幅上升16.695%，现价港币$33.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2548515283","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548515283?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 13:35","pubTimestamp":1751607300,"startTime":"0","endTime":"0","summary":"[上升股]药捷安康－Ｂ(02617) 股价在下午01:35比前收市价大幅上升16.695%，现股价为港币$33.9。至目前为止，今日最高价为$33.9，而最低价为$28.4。总成交量为42.27万股，总成交金额为港币$1.294千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2507042271/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2548636793","title":"四成半IPO募资超1亿美元，上半年44家香港上市、募资1071亿 | 香港IPO市场2025年","url":"https://stock-news.laohu8.com/highlight/detail?id=2548636793","media":"瑞恩资本Ryanbe...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548636793?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 13:22","pubTimestamp":1751606520,"startTime":"0","endTime":"0","summary":"2025年上半年，香港新上市公司共44家，募资1070.61亿，新上市数量较上年同期增14家，募资金额按年增加937亿或 7.01倍。其中的3家已获上市委员会批准除牌。2025年上半年通过IPO上市的42家上市公司一共募资1070.61亿，较2024年同期增加 937亿或701.3%，主要原因是香港IPO市场开始大力回暖、以及越来越多的大型A股公司赴港上市。其中，募资超过1亿美元的IPO共19家，相应募资990.35亿，占全部42家IPO数量的45.2%、全部IPO募资的92.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-07-04/doc-infehues7724473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02617","399300","BK1161","159982","BK1616","00325","02589","HEXmain","09887","BK1587","LU0211977185.USD","BK1213","BK1233"],"gpt_icon":1},{"id":"2548867170","title":"药捷安康-B07月02日遭主力抛售79.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548867170","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548867170?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 16:15","pubTimestamp":1751444150,"startTime":"0","endTime":"0","summary":"07月02日, 药捷安康-B股价跌7.96%，报收27.75元，成交金额2135.3万元，换手率0.25%，振幅12.94%，量比0.47。药捷安康-B今日主力资金净流出79.4万元，上一交易日主力净流出281.0万元。该股近5个交易日上涨14.88%，主力资金累计净流入654.5万元；近20日主力资金累计净流入749.6万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702171029a4cad748&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702171029a4cad748&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2548392003","title":"上半年港股IPO吸金超千亿 科技新秀引爆打新潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2548392003","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548392003?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 18:55","pubTimestamp":1751367300,"startTime":"0","endTime":"0","summary":"在流动性改善、政策面利好等驱动下，港股IPO市场高潮迭起。5 月 20 日，A股巨头宁德时代在港股上市，首发募集资金超410亿港元，位居今年以来港股IPO募资金额第一位，同时也是今年以来全球最大的IPO募资金额。随着港股IPO市场持续活跃，新一轮申报热潮已经来临。安永进一步预测，全年港股IPO募资额有望突破2000亿港元，新上市公司或达80家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701185747953274a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701185747953274a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03288","BK0056","06603","03750","BK0242","09678","01276","159982","603288","09881","06693","02571","SGXZ81163826.USD","BK0127","600988","02609","600276","399300","02097","SGXZ49509284.SGD","02617","02050","02865","BK0132","02589","00325","688169","BK0037","09606","BK0077"],"gpt_icon":0},{"id":"2548072497","title":"智通特供 | 恒指半年检：“港股通冲退榜”显示，这22只股票或将纳入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2548072497","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548072497?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 17:31","pubTimestamp":1751362318,"startTime":"0","endTime":"0","summary":"按照惯例，恒生指数半年检将对上市企业在截至6月30日的12个月内的流动性和市值等指标进行考查，并相应调整指数标的，其中也包括港股通标的。那么，按照当前最新的港股通纳入规则，在下一个港股通检讨日，哪些股票或被纳入港股通呢？根据中信证券测算，2019以来在恒生综指公告日与港股通生效日区间内，预测纳入标的相对恒生综指的平均超额收益达到5.5%。此外，上述这22只股票是在9月份有望纳入港股通，但并不代这22只都要等到9月份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1189","06681","02473","HSTECH","01333","513600","BK1200","HSI","02589","BK1233","BK1549","BK1592","BK1587","BK1239","HSCEI","02833","HSImain","HHImain","BK1175","02617","00506","BK1616","MHImain","YANG","MCHmain","BK4614","BK1161","BK1171"],"gpt_icon":1},{"id":"2547543410","title":"港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快 公司在细分行业研发领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2547543410","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547543410?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 14:41","pubTimestamp":1751265711,"startTime":"0","endTime":"0","summary":"消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼，已获美国食品药物管理局授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司在细分行业研发领先，Tinengotinib是全球首个且唯一进入注册临床阶段用于治疗复发或难治性胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前列腺癌具有临床疗效证据的研究药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161","CCA"],"gpt_icon":1},{"id":"2547505147","title":"61岁医药大佬吴永谦，收获一个IPO！市值突破110亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2547505147","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547505147?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 14:32","pubTimestamp":1751265144,"startTime":"0","endTime":"0","summary":"6月23日，创新药企业药捷安康在港上市，上市首日，其股价大涨超78%。此后数个交易日，药捷安康股价持续上涨，目前其市值已突破100亿港元。截至最新收盘，药捷安康总市值为110亿港元。最新数据显示，截至2025年6月23日，吴永谦直接或者间接持有药捷安康32.98%的股权，而药石科技则持有药捷安康5.57%的股权。若以此计算，吴永谦身价已经超过了36亿港元。2024年6月，药捷安康再次冲击港交所IPO，直至本次才上市成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630143304979439e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630143304979439e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161","BK1574","BK1515","09939"],"gpt_icon":1},{"id":"2547058289","title":"5家创新药企完成新一轮融资，包括药捷安康、华卫恒源等","url":"https://stock-news.laohu8.com/highlight/detail?id=2547058289","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547058289?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 11:35","pubTimestamp":1751254544,"startTime":"0","endTime":"0","summary":"根据梳理，6月23日~6月29日，至少有5家致力于创新药研发的新锐公司宣布完成新一轮融资，包括药捷安康、华卫恒源等。此次药捷安康全球发售以每股13.15港元定价，共发行15,281,000股，募集资金金额达2.01亿港元。资料显示，药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506301139199530bfae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506301139199530bfae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","02617","BK1161"],"gpt_icon":1},{"id":"2547070080","title":"18A新贵，暴涨78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2547070080","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547070080?lang=zh_cn&edition=fundamental","pubTime":"2025-06-29 12:08","pubTimestamp":1751170132,"startTime":"0","endTime":"0","summary":"4月，ADC明星企业映恩生物登陆港交所，创下惊人纪录：募资超2亿美元，首日股价暴涨127%，成为2022年以来“18A”板块最大IPO。2018年4月港交所推出“18A”新政，允许未盈利生物科技公司上市，催生亚洲最大生物科技融资平台。截至2025年3月，已有超70家企业通过“18A”上市，总募资额超千亿港元。根据《2024年港股18A生物科技公司发行投资报告》，截至2024年3月31日，港股“18A”生物科技板块破发企业占比93.75%，股价较发行价平均跌幅71.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629121016a7237c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629121016a7237c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","HSCEI","HSTECH"],"gpt_icon":1},{"id":"2546719632","title":"药捷安康-B06月27日获主力加仓87.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546719632","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546719632?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:15","pubTimestamp":1751012122,"startTime":"0","endTime":"0","summary":"06月27日, 药捷安康-B股价涨5.51%，报收27.75元，成交金额3813.2万元，换手率0.47%，振幅11.41%，量比0.00。药捷安康-B今日主力资金净流入87.4万元，连续4日净流入，上一交易日主力净流入179.1万元。该股近5个交易日上涨112.93%，主力资金累计净流入1109.9万元；近20日主力资金累计净流入1109.9万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627172424a4c0db8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627172424a4c0db8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617"],"gpt_icon":1},{"id":"1178074725","title":"药捷安康-B上市一周累涨逾100%！核心产品替恩戈替尼获FDA快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1178074725","media":"老虎资讯综合","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178074725?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 14:05","pubTimestamp":1751004359,"startTime":"0","endTime":"0","summary":"6月27日，港股次新股$药捷安康-B$午后拉升，上市一周累涨逾100%！药捷安康近日宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼，已获$美国食品$药物管理局授予治疗转移性去势抵抗性前列腺癌的快速通道认证。招股书显示，药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"83994532f58cb7d637e328202e816105","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"药捷安康-B上市一周累涨逾100%！核心产品替恩戈替尼获FDA快速通道认证","news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1141140888","title":"药捷安康-B续涨7%，总市值逼近100亿港元；该股昨日上市首日飙涨近79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141140888","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141140888?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 09:41","pubTimestamp":1750729312,"startTime":"0","endTime":"0","summary":"6月24日，$药捷安康-B(02617)$续涨7%，总市值逼近100亿港元；该股昨日上市首日飙涨近79%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"03e355b77ba35e6757abcf8175791b1c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"2545299104","title":"【湾区早参】深圳二手房在售量超过72000套；广州发布智能网联汽车发展计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2545299104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545299104?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 08:28","pubTimestamp":1750724898,"startTime":"0","endTime":"0","summary":"主要原因为：集团铝合金产品及氧化铝产品销售价格均较2024年同期上涨，销售数量亦有所增加。mCRPC为晚期前列腺癌的一种，属对去势治疗产生耐药并可能出现新转移的病症。此次于美的威灵量产的产品为该集团Gen3.0高压700V半桥氮化镓芯片产品。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1808992512.USD","SG9999014674.SGD","CCA","LU0702159699.USD","BK1594","LU0287142896.SGD","BK1500","LU1166156734.SGD","EMA","02533","BK1237","BK1175","BK1171","LU0173614495.USD","SG9999006597.SGD","02577","LU1224709979.USD","BK1163","IE0034224299.USD","02617","BK4081","BK1592","02338","LU0737861699.HKD","BK1522","SG9999001093.SGD","01378","01497"],"gpt_icon":1},{"id":"2545423968","title":"药捷安康-B(02617.HK)：替恩戈替尼(TT-00420)被授予治疗MCRPC快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423968","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545423968?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 06:33","pubTimestamp":1750717990,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨药捷安康-B发布公告，美国食品药物管理局授予替恩戈替尼治疗转移性去势抵抗性前列腺癌患者的快速通道认证。mCRPC是导致前列腺癌患者死亡的主要因素。替恩戈替尼就治疗CCA获FDA授予孤儿药及快速通道认证，于中国获国家药品监督管理局突破性疗法认证，就治疗胆道癌获EMA孤儿药认证。替恩戈替尼是全球首个和唯一一个有潜力同时抑制FGFR/JAK通路，且针对mCRPC有临床疗效证据的研究药物。主要结果于2024年ASCO GU公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24063351250120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0238689110.USD","LU2229751404.USD","SG9999002224.SGD","LU2764263203.CNY","SG9999002232.USD","BK4585","IE00B3CCJ633.GBP","BK4086","00420","LU0154245673.USD","IE0004086264.USD","IE00BKVL7J92.USD","BK4533","LU0154245756.USD","LU2552382058.USD","IE00BZ1G4Q59.USD","LU2764262908.HKD","LU0323240290.USD","LU0323239441.USD","LU2552382215.SGD","LU2720916845.USD","IE00B2PGVK34.USD","IE00BGHQF417.EUR","LU2463526074.USD","LU2089279066.USD","BK1160","LU2552382132.HKD","02617","LU2211817866.USD","LU2211814178.USD","IE0004091025.USD","BK4588","LU2133065610.SGD","TT","LU2764263039.SGD","BK4504"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}]}}